Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention
This trial is active, not recruiting.
|Treatments||drug-based intervention, lifestyle-based intervention|
|Start date||February 2009|
|End date||September 2011|
|Trial size||3547 participants|
|Trial identifier||NCT00847444, SUCCESS-C Trial|
This is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of Epirubicine-Fluorouracil-Cyclophosphamide(FEC)-chemotherapy, followed by 3 cycles of Docetaxel(D)-chemotherapy, versus 6 cycles of Docetaxel- Cyclophosphamide (DC)-chemotherapy, and to compare the disease free survival in patients with BMI of 24 - 40 kg/m² after randomisation with versus without the lifestyle intervention. Patients will be required to have histopathological proof of a HER2/neu negative tumor and: axillary lymph node metastases (pN1-3) or high risk node negative, defined as: 'pT ≥2 or histopathological grade 3, or age ≤35 or negative hormone receptor status, but are not allowed to have evidence of distant disease. Patients will have to be entered into the study no later than 6 weeks after complete resection of the primary tumor. No other antineoplastic treatment other than surgical treatment, the defined cytotoxic and endocrine treatment and radiotherapy will be allowed prior to study entry and during the course of the study.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
The first primary objective of this study is to compare disease free survival after randomisation in patients treated with a combination of 5-FU/Epirubicine/Cyclophosphamide followed by Docetaxel vs. Docetaxel/Cyclophosphamide
time frame: 60 months
The second primary objective of this study is to compare disease free survival after randomisation in patients with vs. without lifestyle intervention
time frame: 60 months
Female participants at least 18 years old.
Patients may be included in the study only if they meet all the following criteria: 1. Primary epithelial invasive carcinoma of the breast pT1-4, pN0-3, pM0 2. No evidence of HER2/neu overexpressing (IHC neg or +) or amplifying (FISH neg.) tumor 3. Histopathological proof of axillary lymph node metastases (pN1-3) or high risk node negative, defined as at least one criterion of the following: 'pT ≥2, histopathological grade 3, age ≤35, negative hormone receptor' 4. Complete resection of the primary tumor with margins of resection free of invasive carcinoma not more than 6 weeks ago 5. Females ≥ 18 years of age 6. Performance status ≤ 2 on ECOG-Scale 7. Adequate bone marrow reserve: leucocytes ≥ 3.0 x 109/l and platelets ≥ 100 x 109/l 8. Bilirubin within the reference laboratory's normal range, ASAT (SGOT), ALAT (SGPT) and AP within 1,5 fold of the reference laboratory's normal range for patients 9. Willingness to participate in a telephone-based lifestyle intervention programme [10.] Intention of regular follow up visits for the duration of the study [11.] Ability to understand the nature of the study and to give written informed consent Patients will be excluded from the study for any of the following reasons: 1. Inflammatory breast cancer 2. Previous or concomitant cytotoxic or other systemic antineoplastic treatment which is not part of this study 3. A second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) 4. Cardiomyopathy with impaired ventricular function (NYHA > II), cardiac arrhythmias influencing LVEF and requiring medication, history of myocardial infarction or angina pectoris within the last 6 months, or arterial hypertension not being controlled by medication 5. Any known hypersensitivity against Docetaxel, Epirubicine, Cyclophosphamide, or any other medication included in the study protocol. The contraindication, warning notices and measures of precaution of the products, as notified in the product infroamtion, have to be respected 6. Use of any investigational agent within 3 weeks prior to inclusion 7. Patients in pregnancy or breast feeding (in premenopausal women anticonception has to be assured) 8. Insulin-requiring diabetes mellitus (non-insulin requiring patients with type 2 diabetes are eligible for the study) 9. Serious digestive and/or absorptive problems that exclude adherence to the study diet [10.] Self-reported inability to walk at least one kilometer (at any pace) [11.] Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Moderate arthritis that does not preclude physical activity is not a reason for exclusion [12.] Psychiatric disorders or conditions that would preclude participation in the study intervention [13.] Patients not sufficiently fluent in German language to understand the nature of this study and any of the interventional measures
|Official title||Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention Strategies|
|Description||Rationale: - Taxane based chemotherapy will be established as treatment standard in the adjuvant setting of early breast cancer - 3xFEC100, followed by 3xDoc100 has been established as standard treatment option for node-positive breast cancer - Anthracycline based regimens do not seem to be superior in Her2/neu-negative patients (Gennari et al., Slamon et al.) - Dietary intervention can improve outcome in patients with early breast cancer (WINS, Chlebowski et al.) Primary Endpoints: - The first primary objective of this study is to compare disease free survival after randomisation in patients treated with a combination of 5-FU/Epirubicine/Cyclophosphamide followed by Docetaxel vs. Docetaxel/Cyclophosphamide - The second primary objective of this study is to compare disease free survival after randomisation in patients with vs. without lifestyle intervention Design: Prospectively randomized open label Phase III study with 2x2 factorial design|
Call for more information